Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.
ADMA
$8.86
+$0.18 +2.07%

ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.

Market News
11 May 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for allegedly inflating its 2025 revenue growth through channel stuffing, a practice where excess product was pushed to distributors to falsely boost sales figures. This claim surfaced after a report by Culper Research revealed the company’s real revenue likely declined by 3%, not grew 20% as reported. The stock price dropped 29% following the report, prompting legal action for investors who suffered losses. Investors are encouraged to seek legal advice as the investigation continues.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App